AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.19
0.00 (0.00%)
At close: 4:00PM EDT

6.19 0.00 (0.00%)
After hours: 6:07PM EDT

Stock chart is not supported by your current browser
Previous Close6.19
Open6.20
Bid6.15 x 1300
Ask6.21 x 800
Day's Range6.18 - 6.32
52 Week Range5.06 - 7.85
Volume377,323
Avg. Volume499,934
Market Cap561.468M
Beta (3Y Monthly)0.03
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.92
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    ILJIN Chairman Issues Open Letter to Aurinia Shareholders

    ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today issued an open letter to Aurinia shareholders from ILJIN Group Chairman, Mr. Chin Kyu Huh. On June 3, 2019, we, ILJIN SNT Co., Ltd. and its affiliated companies (collectively, the “ILJIN Group”), filed an information circular (the "Circular") seeking to replace three incumbent directors with more capable and independent directors at the upcoming Annual General Meeting of Shareholders of Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) to be held on June 26, 2019.

  • Business Wire5 days ago

    Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reminded shareholders to vote in advance of the proxy voting deadline of 10:00 AM Mountain Time on Monday, June 24, 2019. Aurinia urges shareholders to vote the YELLOW proxy in support of management’s nominees. Aurinia’s Chairman, Dr. George M. Milne, Jr. said: “We are grateful for the support we have received and encourage shareholders to vote the YELLOW proxy today.

  • Business Wire6 days ago

    As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia’s Full Potential

    ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today thanks shareholders for their support ahead of the upcoming Annual General Meeting of Shareholders and encourages all shareholders who haven’t yet voted to vote their GREEN proxy today for the director nominees who are aligned with their interests and are committed to the future success of the company.

  • Business Wire7 days ago

    Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia’s Director Nominees

    Leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have recommended shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) vote the YELLOW proxy card in support of ALL of the Company’s nominees in advance of the upcoming Annual General Meeting of Shareholders (the “AGM”) to be held on Wednesday, June 26, 2019. Shareholders of record as of May 9, 2019 must submit their YELLOW proxy by 10:00 AM Mountain Time on Monday, June 24, 2019.

  • Business Wire14 days ago

    ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts

    ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today filed an investor presentation on SEDAR in connection with the Corporation’s upcoming Annual General Meeting of Shareholders to be held on Wednesday, June 26, 2019. The investor presentation is also available at www.AHealthierAurinia.com.

  • ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information
    Business Wire16 days ago

    ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information

    ILJIN SNT Co., Ltd. (“ILJIN”) today sent a letter to shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (“Aurinia” or the “Corporation”), highlighting the governance failures and director conflicts under the current board of directors, correcting misleading information disseminated to shareholders by Aurinia on June 7, 2019 and urging shareholders to vote their GREEN proxy or GREEN VIF to strengthen the board. ILJIN, a founding shareholder of Aurinia which together with certain affiliates holds an approximately 14% ownership interest in Aurinia, is seeking support for three exceptional nominees for election as directors at the annual meeting: Dr. Robert Foster, Mr. Soon-Yub (Samuel) Kwon and Dr. Myeong-Hee Yu.

  • Business Wire19 days ago

    Aurinia Issues Letter to Shareholders

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today sent a letter to shareholders in connection with the Company’s upcoming Annual General Meeting of Shareholders (“AGM”) to be held on Wednesday, June 26, 2019. Shareholders of record as of May 9, 2019 must submit their YELLOW proxy by 10:00 AM Mountain Time on Monday, June 24, 2019.

  • Business Wire22 days ago

    Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

    Aurinia Pharmaceuticals Inc. today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the fol

  • Business Wire23 days ago

    Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders

    ILJIN SNT Co., Ltd. (“ILJIN”) today announced that it has filed an information circular (the "Circular") and letter to shareholders in connection with the upcoming Annual General Meeting of Shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”) to be held on Wednesday, June 26, 2019. ILJIN, a founding shareholder of Aurinia which together with certain affiliates holds an approximately 14% ownership interest in Aurinia, is seeking support for three exceptional nominees for election as directors at the annual meeting: Dr. Robert Foster, Mr. Soon-Yub (Samuel) Kwon and Dr. Myeong-Hee Yu.

  • Business Wire26 days ago

    Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), today filed its Notice of Meeting and Management Information Circular. Aurinia plans to host its upcoming Annual General Meeting of Shareholders (“AGM”) at 10:00 a.m. MT on Wednesday, June 26, 2019, at the Westin Calgary, 320 4th Ave SW in Calgary, Alberta. The Company also issued a letter to shareholders in response to the receipt of an advance notice of nominees from a minority shareholder who intends to nominate four alternate directors.

  • Business Wirelast month

    Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT in New York, NY.

  • Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss
    Zackslast month

    Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss

    Aurinia (AUPH) delivered earnings and revenue surprises of 0.00% and 0.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Aurinia: 1Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 14 cents per share. Losses, adjusted for non-recurring gains, were 16 cents per share. The results matched Wall Street expectations. The ...

  • Business Wirelast month

    Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights

    - Conference call and webcast to be hosted today at 4:30pm EDT -

  • Business Wire2 months ago

    Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis

    In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. a late clinical-stage biopharmaceutical company with

  • Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks2 months ago

    Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 months ago

    Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s appointment is effective April 29, 2019 concurrent with the previously announced appointment of Mr. Peter Greenleaf as Chief Executive Officer and elevation of Dr. George Milne to Chairman of the Board. “On behalf of the entire organization, it is a pleasure to welcome Daniel onto Aurinia’s Board of Directors.

  • Business Wire2 months ago

    Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

    Aurinia Pharmaceuticals Inc. today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co.

  • Former MedImmune president Greenleaf tapped to lead Canadian biotech
    American City Business Journals2 months ago

    Former MedImmune president Greenleaf tapped to lead Canadian biotech

    Peter Greenleaf was most recently CEO of Baltimore-based Cerecor Inc., a rare disease therapy company that topped the BBJ's list of fastest-growing public companies last year.

  • Business Wire2 months ago

    Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board

    Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors.

  • Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

    Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

  • Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript

    AUPH earnings call for the period ending December 31, 2018.

  • Associated Press3 months ago

    Aurinia: 4Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 17 cents per share. The biotechnology company posted revenue of $29,000 in the period, missing Street forecasts. Three analysts surveyed ...

  • Business Wire3 months ago

    Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

    Aurinia Pharmaceuticals Inc. today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S.